SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Clene plans Phase 3 ALS trial in Q2 2027

Clene plans to initiate the Phase 3 RESTORE-ALS confirmatory trial of CNM-Au8 in the second quarter of 2027.

CLNN

Related stories